Since 2011, the World Orphan Drug Congress USA has been the go to global meeting for stakeholders to meet, dialogue and brainstorm about the challenges and opportunities of orphan drug development.
The 8th Annual World Orphan Drug Congress USA in 2018 will continue to expand the reach of key stakeholders from around the world coming together to discuss ideas and showcase how innovation can expedite rare disease research and bring therapies to patients faster. Key topics include: How to build up successful Expanded Access Programs? How RWE can be effectively incorporated into orphan drug development? How do you price cell and gene therapies? What are the advances in gene editing for rare diseases? Who to partner with to launch orphan drugs in Japan, Latin America, Australia and the Middle East? What is the benefit of genetic testing beyond patient identification and enrollment?
In a sector where collaboration is the key to success, there’s no better opportunity than hearing and networking altogether with leaders from industry, patient advocacy community, researchers, government & regulators, payers, investors and innovative solution providers helping expedite orphan drugs to patients in need.
In 2018, WODC USA will be held at the impressive Gaylord National Harbor Resort & Convention Center in Oxon Hill, MD, in the Washington D.C. metro area. The 250+ speakers and 1,000 attendees from over 50 countries will be spread around 3 days of full content and the following 7 streams:
Global Market Access
Regulatory, Clinical Development / Pricing & Reimbursement
Rare Disease Advocacy World
Pitch & Partner
Patient groups Seminar
On the Pre-conference Day, 5 Workshops will be held covering topics such as: achieving success with a
high performance community of Patients, Advocates and Caregivers; Expanded Access Programs; Business Development & Forecasting; Innovation in rare disease R&D; and Regulatory & Global Market Access success. Along with the workshops the same day will feature 4 seminars covering Next Generation Therapies, Personalized Medicine, Diagnostics, and the successful Payers Seminar, which will once again bring over 15 payers from the US, Europe and around the world to discuss clear guidelines and opportunities to improve pricing & reimbursement negotiations.